Trial Profile

Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 25 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Asciminib (Primary) ; Dasatinib (Primary) ; Imatinib (Primary) ; Nilotinib (Primary)
Indications Chronic myeloid leukaemia
Focus Therapeutic Use

02 Apr 2024 Number of treatment arms are increased from 1 to 3 by the addition of 2 separate combination arms of Asciminib 40 mg with Nilotinib and Asciminib 80 mg with Dasatinib.
13 Dec 2022 Trial design presented at the 64th American Society of Hematology Annual Meeting and Exposition
10 Nov 2021 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com